新西兰制药公司从大公司得到的购买评级很高,这表明投资潜力很大。 Zealand Pharma receives strong-buy ratings from major firms, signaling high investment potential.

丹麦生物技术公司新西兰制药公司从Cantor Fitzgerald公司得到的购买评级很高,JP摩根大通公司获得的超重评级表明投资潜力很大。 Danish biotech company Zealand Pharma received a strong-buy rating from Cantor Fitzgerald and an overweight rating from JPMorgan Chase & Co., indicating strong investment potential. 该公司专门为胃肠道和新陈代谢疾病提供基于丙二酸的药物。 The company specializes in peptide-based medicines for gastrointestinal and metabolic diseases. 其市场上限为73.1亿美元,股票价格为102.98美元,50天平均102.26美元,200天平均117.80美元。 Its market cap is $7.31 billion, with a stock price of $102.98, a 50-day average of $102.26, and a 200-day average of $117.80.